Bengaluru, July 9 -- India's pharmaceutical sector, valued at approximately $55-65 billion in 2025, ranks third globally by volume and fourteenth by value. The industry grew 7.8% year-on-year, supplying 20% of the world's generic medicines and meeting over half of UNICEF's vaccine needs. It is projected to reach $120-130 billion by 2030, driven by innovation and exports.

Nifty Pharma traded flat at 22,208.30 despite Donald Trump's threat of imposing a 200% tariff on pharmaceutical imports to the U.S. The market is likely priced in uncertainty, awaiting clarity on policy execution. Indian pharma's global exposure and regulatory adaptability may have cushioned immediate investor reaction to the geopolitical risk.

The US President's remark...